148 related articles for article (PubMed ID: 8264908)
1. Clinical and pathophysiologic aspects of late levodopa failure.
Poewe W
Neurology; 1993 Dec; 43(12 Suppl 6):S28-30. PubMed ID: 8264908
[TBL] [Abstract][Full Text] [Related]
2. Motor complications associated with chronic levodopa therapy in Parkinson's disease.
Obeso JA; Grandas F; Vaamonde J; Luquin MR; Artieda J; Lera G; Rodriguez ME; Martinez-Lage JM
Neurology; 1989 Nov; 39(11 Suppl 2):11-9. PubMed ID: 2685647
[TBL] [Abstract][Full Text] [Related]
3. Various aspects of motor fluctuations and their management in Parkinson's disease.
Mizuno Y; Kondo T; Mori H
Neurology; 1994 Jul; 44(7 Suppl 6):S29-34. PubMed ID: 8047258
[TBL] [Abstract][Full Text] [Related]
4. Clinical aspects of motor fluctuations in Parkinson's disease.
Poewe WH
Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Cedarbaum JM
Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
[TBL] [Abstract][Full Text] [Related]
6. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
7. [Motor complications in patients with Parkinson disease treated with levodopa].
Luquin MR; Obeso JA; Martínez-Lage JM
Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
[TBL] [Abstract][Full Text] [Related]
8. Preventing levodopa-induced dyskinesias.
Olanow CW; Obeso JA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
10. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Verhagen Metman L
Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
12. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
Calabresi P; Di Filippo M; Ghiglieri V; Tambasco N; Picconi B
Lancet Neurol; 2010 Nov; 9(11):1106-17. PubMed ID: 20880751
[TBL] [Abstract][Full Text] [Related]
14. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
[TBL] [Abstract][Full Text] [Related]
15. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
Obeso JA; Rodriguez-Oroz MC; Rodriguez M; DeLong MR; Olanow CW
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S22-32; discussion S32-4. PubMed ID: 10762129
[TBL] [Abstract][Full Text] [Related]
17. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Tse W
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
[TBL] [Abstract][Full Text] [Related]
18. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Nutt JG; Carter JH; Lea ES; Woodward WR
Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
[TBL] [Abstract][Full Text] [Related]
19. The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Nutt JG; Holford NH
Ann Neurol; 1996 May; 39(5):561-73. PubMed ID: 8619540
[TBL] [Abstract][Full Text] [Related]
20. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
